Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 107

1.
2.

Susceptibility of Meningococcal Strains Responsible for Two Serogroup B Outbreaks on U.S. University Campuses to Serum Bactericidal Activity Elicited by the MenB-4C Vaccine.

Rossi R, Beernink PT, Giuntini S, Granoff DM.

Clin Vaccine Immunol. 2015 Dec;22(12):1227-34. doi: 10.1128/CVI.00474-15. Epub 2015 Sep 30.

4.

Binding of complement factor H to PorB3 and NspA enhances resistance of Neisseria meningitidis to anti-factor H binding protein bactericidal activity.

Giuntini S, Pajon R, Ram S, Granoff DM.

Infect Immun. 2015 Apr;83(4):1536-45. doi: 10.1128/IAI.02984-14. Epub 2015 Feb 2.

5.

Meningococcal factor H binding proteins in epidemic strains from Africa: implications for vaccine development.

Pajon R, Fergus AM, Koeberling O, Caugant DA, Granoff DM.

PLoS Negl Trop Dis. 2011 Sep;5(9):e1302. doi: 10.1371/journal.pntd.0001302. Epub 2011 Sep 6.

6.
7.

Binding of Complement Factor H (FH) Decreases Protective Anti-FH Binding Protein Antibody Responses of Infant Rhesus Macaques Immunized With a Meningococcal Serogroup B Vaccine.

Granoff DM, Costa I, Konar M, Giuntini S, Van Rompay KK, Beernink PT.

J Infect Dis. 2015 Sep 1;212(5):784-92. doi: 10.1093/infdis/jiv081. Epub 2015 Feb 12.

8.

Bactericidal antibody responses induced by meningococcal recombinant chimeric factor H-binding protein vaccines.

Beernink PT, Granoff DM.

Infect Immun. 2008 Jun;76(6):2568-75. doi: 10.1128/IAI.00033-08. Epub 2008 Mar 24.

9.

Broad vaccine coverage predicted for a bivalent recombinant factor H binding protein based vaccine to prevent serogroup B meningococcal disease.

Jiang HQ, Hoiseth SK, Harris SL, McNeil LK, Zhu D, Tan C, Scott AA, Alexander K, Mason K, Miller L, DaSilva I, Mack M, Zhao XJ, Pride MW, Andrew L, Murphy E, Hagen M, French R, Arora A, Jones TR, Jansen KU, Zlotnick GW, Anderson AS.

Vaccine. 2010 Aug 23;28(37):6086-93. doi: 10.1016/j.vaccine.2010.06.083. Epub 2010 Jul 7.

PMID:
20619376
10.

Monoclonal antibodies to meningococcal factor H binding protein with overlapping epitopes and discordant functional activity.

Giuntini S, Beernink PT, Reason DC, Granoff DM.

PLoS One. 2012;7(3):e34272. doi: 10.1371/journal.pone.0034272. Epub 2012 Mar 26.

11.

Two cross-reactive monoclonal antibodies recognize overlapping epitopes on Neisseria meningitidis factor H binding protein but have different functional properties.

Faleri A, Santini L, Brier S, Pansegrau W, Lo Surdo P, Scarselli M, Buricchi F, Volpini G, Genovese A, van der Veen S, Lea S, Tang CM, Savino S, Pizza M, Finco O, Norais N, Masignani V.

FASEB J. 2014 Apr;28(4):1644-53. doi: 10.1096/fj.13-239012. Epub 2013 Dec 26.

13.

Characterization of fHbp, nhba (gna2132), nadA, porA, and sequence type in group B meningococcal case isolates collected in England and Wales during January 2008 and potential coverage of an investigational group B meningococcal vaccine.

Lucidarme J, Comanducci M, Findlow J, Gray SJ, Kaczmarski EB, Guiver M, Vallely PJ, Oster P, Pizza M, Bambini S, Muzzi A, Borrow R.

Clin Vaccine Immunol. 2010 Jun;17(6):919-29. doi: 10.1128/CVI.00027-10. Epub 2010 Apr 7.

14.

Meningococcal factor H-binding protein variants expressed by epidemic capsular group A, W-135, and X strains from Africa.

Beernink PT, Caugant DA, Welsch JA, Koeberling O, Granoff DM.

J Infect Dis. 2009 May 1;199(9):1360-8. doi: 10.1086/597806.

15.

Preclinical evidence for the potential of a bivalent fHBP vaccine to prevent Neisseria meningitidis Serogroup C Disease.

Harris SL, Zhu D, Murphy E, McNeil LK, Wang X, Mayer LW, Harrison LH, Jansen KU, Anderson AS.

Hum Vaccin. 2011 Jan-Feb;7 Suppl:68-74. Epub 2011 Jan 1.

16.

Importance of inhibition of binding of complement factor H for serum bactericidal antibody responses to meningococcal factor H-binding protein vaccines.

Konar M, Granoff DM, Beernink PT.

J Infect Dis. 2013 Aug 15;208(4):627-36. doi: 10.1093/infdis/jit239. Epub 2013 May 28.

17.

Sequence diversity of the factor H binding protein vaccine candidate in epidemiologically relevant strains of serogroup B Neisseria meningitidis.

Murphy E, Andrew L, Lee KL, Dilts DA, Nunez L, Fink PS, Ambrose K, Borrow R, Findlow J, Taha MK, Deghmane AE, Kriz P, Musilek M, Kalmusova J, Caugant DA, Alvestad T, Mayer LW, Sacchi CT, Wang X, Martin D, von Gottberg A, du Plessis M, Klugman KP, Anderson AS, Jansen KU, Zlotnick GW, Hoiseth SK.

J Infect Dis. 2009 Aug 1;200(3):379-89. doi: 10.1086/600141.

PMID:
19534597
18.

A broadly-protective vaccine against meningococcal disease in sub-Saharan Africa based on generalized modules for membrane antigens (GMMA).

Koeberling O, Ispasanie E, Hauser J, Rossi O, Pluschke G, Caugant DA, Saul A, MacLennan CA.

Vaccine. 2014 May 13;32(23):2688-95. doi: 10.1016/j.vaccine.2014.03.068. Epub 2014 Apr 3.

19.

Frequency of factor H-binding protein modular groups and susceptibility to cross-reactive bactericidal activity in invasive meningococcal isolates.

Pajon R, Beernink PT, Harrison LH, Granoff DM.

Vaccine. 2010 Feb 25;28(9):2122-9. doi: 10.1016/j.vaccine.2009.12.027. Epub 2009 Dec 29.

20.

Effect of complement Factor H on anti-FHbp serum bactericidal antibody responses of infant rhesus macaques boosted with a licensed meningococcal serogroup B vaccine.

Giuntini S, Beernink PT, Granoff DM.

Vaccine. 2015 Dec 16;33(51):7168-75. doi: 10.1016/j.vaccine.2015.10.135. Epub 2015 Nov 10.

Supplemental Content

Support Center